Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors

<p dir="ltr">Tyrosine kinase inhibitors (TKIs) have remarkably transformed Ph+ chronic myeloid leukemia (CML) management; however, TKI resistance remains a major clinical challenge. Mutations in <i>BCR-ABL1</i> are well studied but fail to explain 20–40% of resistant case...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Mohamed A. Ismail (418629) (author)
مؤلفون آخرون:	Gheyath K. Nasrallah (9200525) (author), Maria Monne (4166524) (author), Ali AlSayab (17150992) (author), Mohamed A. Yassin (8361183) (author), Govindarajulu Varadharaj (14778931) (author), Salma Younes (6424865) (author), Claudio Sorio (212799) (author), Richard Cook (70389) (author), Helmout Modjtahedi (532099) (author), Nader I. Al-Dewik (14152884) (author)
منشور في:	2022
الموضوعات:	Biological sciences Genetics Biomedical and clinical sciences Cardiovascular medicine and haematology Clinical sciences Chronic Myeloid Leukemia Protein Tyrosine Phosphatase Receptor Type G BCR-ABL1 Single Nucleotide Polymorphisms Tyrosine Kinase Inhibitors Therapeutic Modalities
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors

مواد مشابهة